[
  {
    "objectID": "quarto/index.html",
    "href": "quarto/index.html",
    "title": "Outcomes of Percutaneous Coronary Intervention in Acute Myocardial Infarction Patients with Chronic Kidney Disease: Insights from the National Inpatient Sample",
    "section": "",
    "text": "Reference Papers:\n\nHolzmann et al. (2020)\n\nStudy Objective: Examine the impact of percutaneous coronary intervention (PCI) among inpatient admissions with a principal admission of acute myocardial infarction (MI) and a history of chronic kidney disease (CKD).\nData Source: Cross-sectional analysis of the National Inpatient Sample (NIS) from 2018 to 2020.\nPatient Selection: Included all inpatient admissions with a principal diagnosis of MI and a history of CKD.\nMI + CKD + PCI Categories:\n\nMI + CKD with PCI\nMI + CKD without PCI\n\nPrimary Outcomes:\n\nIn-hospital all-cause mortality\nTotal hospital length of stay (days)\nTotal charge, inflation adjusted to 2020 ($) [adjusted to 2020 dollars, using CPI data by the U.S. Bureau of Labor Statistics]\n\nStatistical Analysis: Multiple logistic and linear regression to determine the independent association of PCI on outcomes, adjusted for:\n\nDemographics: Age, sex, race, insurance, residential income, and residential region.\nMedical History: MI type, CKD class, prior MI, and prior PCI.\nComorbidities: Charlson comorbidity index, atrial fibrillation, cerebrovascular disease, heart failure, diabetes mellitus, hyperlipidemia, hypertension, and peripheral vascular disease.\n\nSoftware: All analyses were performed using R Version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria)"
  },
  {
    "objectID": "quarto/index.html#preamble",
    "href": "quarto/index.html#preamble",
    "title": "Outcomes of Percutaneous Coronary Intervention in Acute Myocardial Infarction Patients with Chronic Kidney Disease: Insights from the National Inpatient Sample",
    "section": "",
    "text": "Reference Papers:\n\nHolzmann et al. (2020)\n\nStudy Objective: Examine the impact of percutaneous coronary intervention (PCI) among inpatient admissions with a principal admission of acute myocardial infarction (MI) and a history of chronic kidney disease (CKD).\nData Source: Cross-sectional analysis of the National Inpatient Sample (NIS) from 2018 to 2020.\nPatient Selection: Included all inpatient admissions with a principal diagnosis of MI and a history of CKD.\nMI + CKD + PCI Categories:\n\nMI + CKD with PCI\nMI + CKD without PCI\n\nPrimary Outcomes:\n\nIn-hospital all-cause mortality\nTotal hospital length of stay (days)\nTotal charge, inflation adjusted to 2020 ($) [adjusted to 2020 dollars, using CPI data by the U.S. Bureau of Labor Statistics]\n\nStatistical Analysis: Multiple logistic and linear regression to determine the independent association of PCI on outcomes, adjusted for:\n\nDemographics: Age, sex, race, insurance, residential income, and residential region.\nMedical History: MI type, CKD class, prior MI, and prior PCI.\nComorbidities: Charlson comorbidity index, atrial fibrillation, cerebrovascular disease, heart failure, diabetes mellitus, hyperlipidemia, hypertension, and peripheral vascular disease.\n\nSoftware: All analyses were performed using R Version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria)"
  },
  {
    "objectID": "quarto/index.html#baseline-table",
    "href": "quarto/index.html#baseline-table",
    "title": "Outcomes of Percutaneous Coronary Intervention in Acute Myocardial Infarction Patients with Chronic Kidney Disease: Insights from the National Inpatient Sample",
    "section": "Baseline Table:",
    "text": "Baseline Table:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall, N = 370,3551\nNo PCI, N = 238,2301\nPCI, N = 132,1251\np-value2\n\n\n\n\nAge, y\n72 (12)\n73 (12)\n71 (12)\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n&lt;0.001\n\n\n    Female\n144,245 (39)\n96,310 (40)\n47,935 (36)\n\n\n\n\n    Male\n226,100 (61)\n141,915 (60)\n84,185 (64)\n\n\n\n\nRace\n\n\n\n\n\n\n&lt;0.001\n\n\n    White\n243,110 (67)\n153,130 (66)\n89,980 (70)\n\n\n\n\n    Asian or Pacific Islander\n13,630 (3.8)\n8,980 (3.9)\n4,650 (3.6)\n\n\n\n\n    Black\n57,540 (16)\n39,465 (17)\n18,075 (14)\n\n\n\n\n    Hispanic\n35,620 (9.8)\n23,770 (10)\n11,850 (9.2)\n\n\n\n\n    Native American\n2,575 (0.7)\n1,550 (0.7)\n1,025 (0.8)\n\n\n\n\n    Other\n9,375 (2.6)\n5,845 (2.5)\n3,530 (2.7)\n\n\n\n\nMI type\n\n\n\n\n\n\n&lt;0.001\n\n\n    Non-ST-elevation MI\n295,415 (80)\n199,050 (84)\n96,365 (73)\n\n\n\n\n    Other MI\n25,685 (6.9)\n23,975 (10)\n1,710 (1.3)\n\n\n\n\n    ST-elevation MI\n49,255 (13)\n15,205 (6.4)\n34,050 (26)\n\n\n\n\nCKD stage\n\n\n\n\n\n\n&lt;0.001\n\n\n    CKD, Stage 1\n2,350 (0.6)\n1,315 (0.6)\n1,035 (0.8)\n\n\n\n\n    CKD, Stage 2\n24,960 (6.7)\n14,420 (6.1)\n10,540 (8.0)\n\n\n\n\n    CKD, Stage 3\n204,195 (55)\n128,175 (54)\n76,020 (58)\n\n\n\n\n    CKD, Stage 4\n51,995 (14)\n38,025 (16)\n13,970 (11)\n\n\n\n\n    CKD, Stage 5\n6,310 (1.7)\n4,780 (2.0)\n1,530 (1.2)\n\n\n\n\n    ESKD\n80,545 (22)\n51,515 (22)\n29,030 (22)\n\n\n\n\nCharlson comorbidity index\n5.77 (1.56)\n5.86 (1.56)\n5.60 (1.53)\n&lt;0.001\n\n\nExpected primary payer\n\n\n\n\n\n\n&lt;0.001\n\n\n    Private\n51,290 (14)\n30,075 (13)\n21,215 (16)\n\n\n\n\n    Medicaid\n24,220 (6.5)\n16,005 (6.7)\n8,215 (6.2)\n\n\n\n\n    Medicare\n286,270 (77)\n186,820 (78)\n99,450 (75)\n\n\n\n\n    Other\n8,235 (2.2)\n5,120 (2.2)\n3,115 (2.4)\n\n\n\n\nResidential income\n\n\n\n\n\n\n&lt;0.001\n\n\n    $1 - $51,999\n116,335 (32)\n76,345 (33)\n39,990 (31)\n\n\n\n\n    $52,000 - $65,999\n101,180 (28)\n65,020 (28)\n36,160 (28)\n\n\n\n\n    $66,000 - $87,999\n84,550 (23)\n53,280 (23)\n31,270 (24)\n\n\n\n\n    $88,000 or more\n62,630 (17)\n39,890 (17)\n22,740 (17)\n\n\n\n\nResidential region\n\n\n\n\n\n\n0.21\n\n\n    Large metro\n184,075 (50)\n118,915 (50)\n65,160 (49)\n\n\n\n\n    Micropolitan\n72,225 (20)\n46,520 (20)\n25,705 (19)\n\n\n\n\n    Small metro\n113,030 (31)\n72,040 (30)\n40,990 (31)\n\n\n\n\nAtrial fibrillation\n94,270 (25)\n65,985 (28)\n28,285 (21)\n&lt;0.001\n\n\nCerebrovascular disease\n35,430 (9.6)\n24,575 (10)\n10,855 (8.2)\n&lt;0.001\n\n\nHeart failure\n247,410 (67)\n166,625 (70)\n80,785 (61)\n&lt;0.001\n\n\nDiabetes mellitus\n233,395 (63)\n149,000 (63)\n84,395 (64)\n&lt;0.001\n\n\nHyperlipidemia\n267,640 (72)\n166,840 (70)\n100,800 (76)\n&lt;0.001\n\n\nHypertension\n354,700 (96)\n228,345 (96)\n126,355 (96)\n0.17\n\n\nPeripheral vascular disease\n64,435 (17)\n43,840 (18)\n20,595 (16)\n&lt;0.001\n\n\nPrior MI\n79,360 (21)\n50,955 (21)\n28,405 (21)\n0.74\n\n\nPrior PCI\n75,000 (20)\n47,530 (20)\n27,470 (21)\n0.008\n\n\n\n1 Mean (SD); n (%)\n\n\n2 Wilcoxon rank-sum test for complex survey samples; chi-squared test with Rao & Scott’s second-order correction"
  },
  {
    "objectID": "quarto/index.html#outcomes-table",
    "href": "quarto/index.html#outcomes-table",
    "title": "Outcomes of Percutaneous Coronary Intervention in Acute Myocardial Infarction Patients with Chronic Kidney Disease: Insights from the National Inpatient Sample",
    "section": "Outcomes Table:",
    "text": "Outcomes Table:\n\n\n\n\n\n\n\n\nCharacteristic\nOverall, N = 370,3551\nNo PCI, N = 238,2301\nPCI, N = 132,1251\np-value2\n\n\n\n\nDied during hospitalization\n24,765 (6.7)\n17,630 (7.4)\n7,135 (5.4)\n&lt;0.001\n\n\nLength of stay (days)\n4.0 (2.0 – 7.0)\n4.0 (2.0 – 8.0)\n4.0 (2.0 – 7.0)\n&lt;0.001\n\n\nInflation-adjusted total charge ($)\n71,586 (36,593 – 136,805)\n49,014 (26,741 – 104,518)\n106,876 (72,323 – 170,451)\n&lt;0.001\n\n\n\n1 n (%); Median (IQR)\n\n\n2 chi-squared test with Rao & Scott’s second-order correction; Wilcoxon rank-sum test for complex survey samples"
  },
  {
    "objectID": "quarto/index.html#multivariable-logistic-regression",
    "href": "quarto/index.html#multivariable-logistic-regression",
    "title": "Outcomes of Percutaneous Coronary Intervention in Acute Myocardial Infarction Patients with Chronic Kidney Disease: Insights from the National Inpatient Sample",
    "section": "Multivariable Logistic Regression:",
    "text": "Multivariable Logistic Regression:\n\nAll-Cause Mortality:\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR (95% CI)1\np-value\n\n\n\n\nPCI status\n\n\n\n\n\n\n    No PCI\n—\n\n\n\n\n    PCI\n0.60 (0.55 to 0.64)\n&lt;0.001\n\n\nAge, y\n1.03 (1.03 to 1.03)\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n    Female\n—\n\n\n\n\n    Male\n0.98 (0.92 to 1.04)\n0.44\n\n\nRace\n\n\n\n\n\n\n    White\n—\n\n\n\n\n    Asian or Pacific Islander\n1.13 (0.96 to 1.32)\n0.13\n\n\n    Black\n0.86 (0.78 to 0.95)\n0.002\n\n\n    Hispanic\n0.95 (0.85 to 1.06)\n0.35\n\n\n    Native American\n1.31 (0.93 to 1.86)\n0.12\n\n\n    Other\n0.99 (0.82 to 1.19)\n0.90\n\n\nMI type\n\n\n\n\n\n\n    Non-ST-elevation MI\n—\n\n\n\n\n    Other MI\n0.79 (0.69 to 0.90)\n&lt;0.001\n\n\n    ST-elevation MI\n3.76 (3.47 to 4.06)\n&lt;0.001\n\n\nCKD stage\n\n\n\n\n\n\n    CKD, Stage 1\n—\n\n\n\n\n    CKD, Stage 2\n1.23 (0.72 to 2.11)\n0.45\n\n\n    CKD, Stage 3\n1.61 (0.95 to 2.72)\n0.075\n\n\n    CKD, Stage 4\n2.12 (1.25 to 3.60)\n0.005\n\n\n    CKD, Stage 5\n2.89 (1.66 to 5.03)\n&lt;0.001\n\n\n    ESKD\n3.43 (2.03 to 5.79)\n&lt;0.001\n\n\nCharlson comorbidity index\n1.07 (1.04 to 1.10)\n&lt;0.001\n\n\nExpected primary payer\n\n\n\n\n\n\n    Private\n—\n\n\n\n\n    Medicaid\n0.83 (0.70 to 0.99)\n0.036\n\n\n    Medicare\n0.96 (0.86 to 1.06)\n0.42\n\n\n    Other\n1.00 (0.79 to 1.25)\n0.98\n\n\nResidential income\n\n\n\n\n\n\n    $1 - $51,999\n—\n\n\n\n\n    $52,000 - $65,999\n1.03 (0.95 to 1.12)\n0.49\n\n\n    $66,000 - $87,999\n1.00 (0.92 to 1.10)\n0.94\n\n\n    $88,000 or more\n1.08 (0.98 to 1.19)\n0.11\n\n\nResidential region\n\n\n\n\n\n\n    Large metro\n—\n\n\n\n\n    Micropolitan\n1.01 (0.92 to 1.11)\n0.83\n\n\n    Small metro\n1.06 (0.98 to 1.14)\n0.12\n\n\nAtrial fibrillation\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.22 (1.14 to 1.30)\n&lt;0.001\n\n\nCerebrovascular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.24 (1.12 to 1.37)\n&lt;0.001\n\n\nHeart failure\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.75 (1.61 to 1.90)\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.86 (0.80 to 0.94)\n&lt;0.001\n\n\nHyperlipidemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.61 (0.57 to 0.65)\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.74 (0.65 to 0.85)\n&lt;0.001\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.07 (0.98 to 1.16)\n0.13\n\n\nPrior MI\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.80 (0.73 to 0.86)\n&lt;0.001\n\n\nPrior PCI\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.72 (0.66 to 0.79)\n&lt;0.001\n\n\n\n1 OR = Odds Ratio, CI = Confidence Interval"
  },
  {
    "objectID": "quarto/index.html#multivariable-linear-regression",
    "href": "quarto/index.html#multivariable-linear-regression",
    "title": "Outcomes of Percutaneous Coronary Intervention in Acute Myocardial Infarction Patients with Chronic Kidney Disease: Insights from the National Inpatient Sample",
    "section": "Multivariable Linear Regression:",
    "text": "Multivariable Linear Regression:\n\nLength of Stay:\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta (95% CI)1\np-value\n\n\n\n\nPCI status\n\n\n\n\n\n\n    No PCI\n—\n\n\n\n\n    PCI\n-0.38 (-0.49 to -0.27)\n&lt;0.001\n\n\nAge, y\n-0.02 (-0.03 to -0.02)\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n    Female\n—\n\n\n\n\n    Male\n0.12 (0.02 to 0.22)\n0.015\n\n\nRace\n\n\n\n\n\n\n    White\n—\n\n\n\n\n    Asian or Pacific Islander\n0.11 (-0.20 to 0.43)\n0.48\n\n\n    Black\n-0.16 (-0.33 to 0.00)\n0.054\n\n\n    Hispanic\n0.21 (-0.01 to 0.42)\n0.060\n\n\n    Native American\n0.26 (-0.41 to 0.93)\n0.45\n\n\n    Other\n0.51 (0.11 to 0.90)\n0.012\n\n\nMI type\n\n\n\n\n\n\n    Non-ST-elevation MI\n—\n\n\n\n\n    Other MI\n-1.1 (-1.3 to -0.96)\n&lt;0.001\n\n\n    ST-elevation MI\n0.32 (0.15 to 0.49)\n&lt;0.001\n\n\nCKD stage\n\n\n\n\n\n\n    CKD, Stage 1\n—\n\n\n\n\n    CKD, Stage 2\n-0.07 (-0.56 to 0.41)\n0.77\n\n\n    CKD, Stage 3\n0.05 (-0.42 to 0.52)\n0.84\n\n\n    CKD, Stage 4\n0.53 (0.04 to 1.0)\n0.033\n\n\n    CKD, Stage 5\n0.36 (-0.21 to 0.93)\n0.22\n\n\n    ESKD\n0.98 (0.48 to 1.5)\n&lt;0.001\n\n\nCharlson comorbidity index\n0.21 (0.16 to 0.25)\n&lt;0.001\n\n\nExpected primary payer\n\n\n\n\n\n\n    Private\n—\n\n\n\n\n    Medicaid\n0.15 (-0.15 to 0.45)\n0.33\n\n\n    Medicare\n-0.33 (-0.51 to -0.16)\n&lt;0.001\n\n\n    Other\n-0.03 (-0.37 to 0.32)\n0.88\n\n\nResidential income\n\n\n\n\n\n\n    $1 - $51,999\n—\n\n\n\n\n    $52,000 - $65,999\n-0.14 (-0.28 to -0.01)\n0.032\n\n\n    $66,000 - $87,999\n-0.09 (-0.24 to 0.05)\n0.21\n\n\n    $88,000 or more\n-0.20 (-0.38 to -0.02)\n0.026\n\n\nResidential region\n\n\n\n\n\n\n    Large metro\n—\n\n\n\n\n    Micropolitan\n-0.59 (-0.74 to -0.44)\n&lt;0.001\n\n\n    Small metro\n-0.35 (-0.49 to -0.21)\n&lt;0.001\n\n\nAtrial fibrillation\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.2 (1.1 to 1.3)\n&lt;0.001\n\n\nCerebrovascular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.9 (1.7 to 2.1)\n&lt;0.001\n\n\nHeart failure\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n2.0 (1.8 to 2.1)\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.02 (-0.11 to 0.16)\n0.74\n\n\nHyperlipidemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.90 (-1.0 to -0.77)\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.31 (-0.64 to 0.02)\n0.064\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.32 (-0.45 to -0.19)\n&lt;0.001\n\n\nPrior MI\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-1.0 (-1.1 to -0.94)\n&lt;0.001\n\n\nPrior PCI\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-1.1 (-1.2 to -1.0)\n&lt;0.001\n\n\n\n1 CI = Confidence Interval\n\n\n\n\n\n\n\n\n\n\nInflation Adjusted Total Charge:\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta (95% CI)1\np-value\n\n\n\n\nPCI status\n\n\n\n\n\n\n    No PCI\n—\n\n\n\n\n    PCI\n44,193 (41,016 to 47,371)\n&lt;0.001\n\n\nAge, y\n-1,011 (-1,133 to -889)\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n    Female\n—\n\n\n\n\n    Male\n10,397 (7,955 to 12,839)\n&lt;0.001\n\n\nRace\n\n\n\n\n\n\n    White\n—\n\n\n\n\n    Asian or Pacific Islander\n28,076 (17,763 to 38,389)\n&lt;0.001\n\n\n    Black\n-14,427 (-18,581 to -10,273)\n&lt;0.001\n\n\n    Hispanic\n28,670 (22,738 to 34,602)\n&lt;0.001\n\n\n    Native American\n6,021 (-9,821 to 21,864)\n0.46\n\n\n    Other\n32,633 (18,646 to 46,620)\n&lt;0.001\n\n\nMI type\n\n\n\n\n\n\n    Non-ST-elevation MI\n—\n\n\n\n\n    Other MI\n-38,587 (-42,183 to -34,991)\n&lt;0.001\n\n\n    ST-elevation MI\n24,801 (20,027 to 29,575)\n&lt;0.001\n\n\nCKD stage\n\n\n\n\n\n\n    CKD, Stage 1\n—\n\n\n\n\n    CKD, Stage 2\n-8,449 (-24,431 to 7,532)\n0.30\n\n\n    CKD, Stage 3\n-11,802 (-27,564 to 3,960)\n0.14\n\n\n    CKD, Stage 4\n-13,606 (-29,639 to 2,426)\n0.10\n\n\n    CKD, Stage 5\n-15,398 (-33,151 to 2,354)\n0.089\n\n\n    ESKD\n16,519 (-124 to 33,163)\n0.052\n\n\nCharlson comorbidity index\n-142 (-1,272 to 989)\n0.81\n\n\nExpected primary payer\n\n\n\n\n\n\n    Private\n—\n\n\n\n\n    Medicaid\n-8,030 (-14,907 to -1,154)\n0.022\n\n\n    Medicare\n-6,622 (-11,763 to -1,481)\n0.012\n\n\n    Other\n2,444 (-6,602 to 11,491)\n0.60\n\n\nResidential income\n\n\n\n\n\n\n    $1 - $51,999\n—\n\n\n\n\n    $52,000 - $65,999\n-2,613 (-5,974 to 747)\n0.13\n\n\n    $66,000 - $87,999\n-784 (-4,820 to 3,252)\n0.70\n\n\n    $88,000 or more\n613 (-4,807 to 6,034)\n0.82\n\n\nResidential region\n\n\n\n\n\n\n    Large metro\n—\n\n\n\n\n    Micropolitan\n-31,807 (-36,133 to -27,480)\n&lt;0.001\n\n\n    Small metro\n-15,712 (-20,620 to -10,804)\n&lt;0.001\n\n\nAtrial fibrillation\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n25,841 (22,718 to 28,965)\n&lt;0.001\n\n\nCerebrovascular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n38,333 (33,494 to 43,172)\n&lt;0.001\n\n\nHeart failure\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n34,707 (31,807 to 37,607)\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n6,779 (3,313 to 10,245)\n&lt;0.001\n\n\nHyperlipidemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-15,983 (-19,334 to -12,632)\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-7,238 (-15,430 to 955)\n0.083\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-2,109 (-5,849 to 1,630)\n0.27\n\n\nPrior MI\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-20,827 (-23,365 to -18,289)\n&lt;0.001\n\n\nPrior PCI\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-23,297 (-25,830 to -20,765)\n&lt;0.001\n\n\n\n1 CI = Confidence Interval"
  }
]